Free Trial

Lucid Diagnostics (LUCD) Competitors

Lucid Diagnostics logo
$1.24 +0.05 (+3.78%)
As of 11:29 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

LUCD vs. AVNS, ZIMV, KIDS, CBLL, SMLR, TMCI, DCTH, DRTS, NPCE, and RXST

Should you be buying Lucid Diagnostics stock or one of its competitors? The main competitors of Lucid Diagnostics include Avanos Medical (AVNS), ZimVie (ZIMV), OrthoPediatrics (KIDS), CeriBell (CBLL), Semler Scientific (SMLR), Treace Medical Concepts (TMCI), Delcath Systems (DCTH), Alpha Tau Medical (DRTS), NeuroPace (NPCE), and RxSight (RXST). These companies are all part of the "medical equipment" industry.

Lucid Diagnostics vs. Its Competitors

Lucid Diagnostics (NASDAQ:LUCD) and AVANOS MEDICAL (NYSE:AVNS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation and risk.

Lucid Diagnostics has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500. Comparatively, AVANOS MEDICAL has a beta of 1.15, indicating that its share price is 15% more volatile than the S&P 500.

AVANOS MEDICAL has a net margin of -66.89% compared to Lucid Diagnostics' net margin of -1,476.35%. AVANOS MEDICAL's return on equity of 6.16% beat Lucid Diagnostics' return on equity.

Company Net Margins Return on Equity Return on Assets
Lucid Diagnostics-1,476.35% N/A -120.43%
AVANOS MEDICAL -66.89%6.16%4.57%

Lucid Diagnostics presently has a consensus price target of $3.70, indicating a potential upside of 199.60%. Given Lucid Diagnostics' stronger consensus rating and higher probable upside, analysts clearly believe Lucid Diagnostics is more favorable than AVANOS MEDICAL.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lucid Diagnostics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67
AVANOS MEDICAL
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50

Lucid Diagnostics has higher earnings, but lower revenue than AVANOS MEDICAL. AVANOS MEDICAL is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lucid Diagnostics$4.36M37.81-$45.53M-$1.19-1.04
AVANOS MEDICAL$687.80M0.75-$392.10M-$10.07-1.11

74.0% of Lucid Diagnostics shares are held by institutional investors. Comparatively, 95.2% of AVANOS MEDICAL shares are held by institutional investors. 6.8% of Lucid Diagnostics shares are held by company insiders. Comparatively, 2.6% of AVANOS MEDICAL shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Lucid Diagnostics had 3 more articles in the media than AVANOS MEDICAL. MarketBeat recorded 5 mentions for Lucid Diagnostics and 2 mentions for AVANOS MEDICAL. Lucid Diagnostics' average media sentiment score of 0.70 beat AVANOS MEDICAL's score of 0.30 indicating that Lucid Diagnostics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Lucid Diagnostics
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
AVANOS MEDICAL
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Lucid Diagnostics beats AVANOS MEDICAL on 11 of the 16 factors compared between the two stocks.

Get Lucid Diagnostics News Delivered to You Automatically

Sign up to receive the latest news and ratings for LUCD and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LUCD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LUCD vs. The Competition

MetricLucid DiagnosticsMED INSTRUMENTS IndustryMedical SectorNASDAQ Exchange
Market Cap$164.84M$6.92B$6.06B$10.57B
Dividend YieldN/A1.18%5.73%4.80%
P/E Ratio-1.0426.3685.0727.47
Price / Sales37.8128.02518.67200.70
Price / CashN/A21.5837.5761.53
Price / Book-1.585.2112.336.87
Net Income-$45.53M$178.09M$3.32B$276.69M
7 Day Performance1.23%-1.91%0.70%0.70%
1 Month Performance16.51%6.15%10.27%8.83%
1 Year Performance56.33%6.59%74.67%36.06%

Lucid Diagnostics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LUCD
Lucid Diagnostics
3.0987 of 5 stars
$1.24
+3.8%
$3.70
+199.6%
+52.7%$164.84M$4.36M-1.0470News Coverage
Analyst Upgrade
AVNS
Avanos Medical
1.5017 of 5 stars
$11.57
-1.9%
N/A-51.5%$547.08M$692.50M-1.152,227Positive News
Analyst Forecast
ZIMV
ZimVie
1.1699 of 5 stars
$18.92
-0.1%
$17.75
-6.2%
+20.1%$534.31M$449.75M-27.031,770
KIDS
OrthoPediatrics
4.6244 of 5 stars
$18.24
-2.8%
$34.14
+87.2%
-31.9%$470.64M$220.73M-10.19200Positive News
CBLL
CeriBell
2.0793 of 5 stars
$12.57
-0.6%
$32.14
+155.7%
N/A$463.43M$65.44M-4.20N/APositive News
SMLR
Semler Scientific
3.2113 of 5 stars
$30.75
+0.6%
$74.25
+141.5%
-6.5%$452.43M$56.29M12.65120Gap Up
TMCI
Treace Medical Concepts
2.3021 of 5 stars
$6.30
-0.9%
$9.83
+56.1%
+19.2%$401.78M$209.36M-7.97250Analyst Forecast
DCTH
Delcath Systems
2.6002 of 5 stars
$10.80
-2.7%
$24.50
+126.9%
+30.2%$388.29M$37.21M216.0060Analyst Downgrade
Gap Up
DRTS
Alpha Tau Medical
2.2338 of 5 stars
$4.22
-2.1%
$9.00
+113.3%
+82.9%$365.57MN/A-8.7980Gap Down
NPCE
NeuroPace
3.5751 of 5 stars
$10.77
-1.4%
$16.60
+54.1%
+67.5%$361.25M$79.91M-12.82170Positive News
RXST
RxSight
2.8275 of 5 stars
$8.49
-3.5%
$10.00
+17.8%
-84.6%$360.06M$139.93M-10.61220

Related Companies and Tools


This page (NASDAQ:LUCD) was last updated on 10/15/2025 by MarketBeat.com Staff
From Our Partners